Linked Life Data

19090877

Source:http://linkedlifedata.com/resource/pubmed/id/19090877

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2008-12-18
pubmed:abstractText
Diabetic nephropathy management should include the use of an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker with additional antihypertensive medications to reduce proteinuria and cardiovascular events. Some studies suggest that adding a nondihydropyridine rather than a dihydropyridine calcium channel blocker (CCB) may more effectively lower proteinuria. We hypothesized that a trandolapril/verapamil SR (T/V) fixed-dose combination (FDC) was superior to a benazepril/amlodipine (B/A) FDC for reducing albuminuria in 304 hypertensive diabetic nephropathy patients when treated for 36 weeks. No statistically significant differences were observed between groups in the primary end point; adjusted percentage change in urinary albumin/creatinine ratio (UACR), which increased (mean T/V, 29.29%; mean B/A, 8.49%; difference, 20.80%; P=.34); or in change in absolute UACR, which decreased (mean [g/g] T/V, -0.11; mean [g/g] B/A, -0.08; difference -0.03; P=.78). There were significant reductions in log UACR (mean change in T/V, -0.28; P<.01; mean change in B/A, -0.31; P<.001) and diastolic blood pressure in both groups and in systolic blood pressure in the B/A group. T/V was not superior to B/A for reducing UACR. Both ACEI/CCB FDCs may reduce albuminuria; in the case of T/V, this appears to be independent of systolic blood pressure reduction in patients who had previously been treated and had baseline blood pressure levels of 142/77 mm Hg.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1524-6175
pubmed:author
pubmed:issnType
Print
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
761-9
pubmed:meshHeading
pubmed-meshheading:19090877-Aged, pubmed-meshheading:19090877-Albuminuria, pubmed-meshheading:19090877-Amlodipine, pubmed-meshheading:19090877-Angiotensin-Converting Enzyme Inhibitors, pubmed-meshheading:19090877-Antihypertensive Agents, pubmed-meshheading:19090877-Benzazepines, pubmed-meshheading:19090877-Blood Pressure, pubmed-meshheading:19090877-Calcium Channel Blockers, pubmed-meshheading:19090877-Diabetes Mellitus, Type 2, pubmed-meshheading:19090877-Diabetic Nephropathies, pubmed-meshheading:19090877-Drug Synergism, pubmed-meshheading:19090877-Drug Therapy, Combination, pubmed-meshheading:19090877-Female, pubmed-meshheading:19090877-Humans, pubmed-meshheading:19090877-Indoles, pubmed-meshheading:19090877-Male, pubmed-meshheading:19090877-Middle Aged, pubmed-meshheading:19090877-Prospective Studies, pubmed-meshheading:19090877-Proteinuria, pubmed-meshheading:19090877-Treatment Outcome, pubmed-meshheading:19090877-Verapamil
pubmed:year
2008
pubmed:articleTitle
Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy.
pubmed:affiliation
Department of Internal Medicine, Division of Nephrology, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8856, USA. robert.toto@utsouthwestern.edu
pubmed:publicationType
Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Research Support, N.I.H., Extramural